Sigachi Industries Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹113 Cr +35.2% YoYSee revenue, profit and what management said. You are viewing Q3 FY26.
S

Sigachi Industries Ltd

Q3 FY26Pharmaceuticals & Biotechnology

Sigachi Industries Q3 FY26 earnings call: Revenue & Margins

Q3 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹92Cr
−12.4% YoY
+9.6% QoQ
Net profit
₹3Cr
−69.7% YoY
−75.1% QoQ
Margin
7.79%
−12.4 pp YoY
−0.2 pp QoQ
Price₹30
Market cap₹995 Cr
P/E30.6

The short version

Sigachi anticipates resumption of normalcy in operations with additional capacities coming online, especially the 12,000 metric tons per annum MCC expansion at Dahej, expected by Q3 FY27. FY27 is expected to see normalization and growth with the commissioning of expanded capacities at the Dahej facility (12,000 MT capacity), targeting Q3 FY27.

From Sigachi Industries Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Sigachi anticipates resumption of normalcy in operations with additional capacities coming online, especially the 12,000 metric tons per annum MCC expansion at Dahej, expected by Q3 FY27.
  • Total cellulose-based excipient capacity will rise to 30,000 metric tons per annum post expansion.
  • FY27 is expected to see partial recovery in production and margins, with a more significant improvement from FY28 onwards.
  • Revenue growth of around 25% was targeted pre-incident; FY27 growth will be impacted but expected to normalize gradually.
  • The company is confident of consistent and sustainable growth over the next 2-3 years, driven by expansion in excipient capacities, API initiatives, and O&M services.
  • API revenue from Cystic Fibrosis product is expected to commercialize with INR 250 crore revenue potential after 12 months.

2 more points from Sigachi Industries Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Sigachi Industries Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Sigachi Industries is undertaking a capacity expansion at the Dahej SEZ facility:
  • 12,000 metric tons per annum MCC capacity expansion expected to commission by Q3 FY27.
  • 1,800 tons CCS disintegrant facility at Dahej SEZ is also progressing, targeting the same Q3 FY27 commissioning.
  • No long-term debt currently; working capital debt only.
  • For completion of capex, company may raise equity or debt based on board decisions.
  • Capex plans also include further projects beyond Dahej, including CCS facility.
  • Exact equity/debt raise amounts are not finalized; company will announce at appropriate time.

2 more points from Sigachi Industries Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Sigachi Industries Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Sigachi Industries Ltd said on order book & pipeline — free account, 30 seconds.

Sigachi Industries Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Sigachi Industries Ltd Q3 FY26 results — key figures

Sigachi Industries Ltd Q3 FY26 reported results vs Q3 FY25, ₹ crore
₹ CrQ3 FY26Q3 FY25YoYQ2 FY26QoQ
Revenue92105-12.4%84+9.6%
Operating profit (EBITDA)721-66.2%7+7.5%
Operating margin7.79%20.17%-12.4 pp7.95%-0.2 pp
Profit before tax116-93.7%8-87.3%
Net profit (PAT)310-69.7%12-75.1%
EPS (₹)0.080.29-72.4%0.31-74.2%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹113 Cr, net profit ₹9 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Natural Capsules (Q3 FY26)

    Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks

  • Wanbury (Q3 FY26)

    Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Gujarat Themis Biosyn (Q3 FY26)

    43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Balaxi Pharma (Q3 FY26)

    Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Sigachi Industries Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Sigachi Industries Ltd Q3 FY26 results?

Sigachi anticipates resumption of normalcy in operations with additional capacities coming online, especially the 12,000 metric tons per annum MCC expansion at Dahej, expected by Q3 FY27. FY27 is expected to see normalization and growth with the commissioning of expanded capacities at the Dahej facility (12,000 MT capacity), targeting Q3 FY27.

What is Sigachi Industries Ltd share price analysis?

Sigachi Industries Ltd currently shows a neutral. The stock trades at a P/E of 30.6 with a market cap of ₹995 Cr. Investors should review the full earnings analysis for detailed insights.

Is Sigachi Industries Ltd planning capital expenditure?

Sigachi Industries is undertaking a capacity expansion at the Dahej SEZ facility: - 12,000 metric tons per annum MCC capacity expansion expected to commission by Q3 FY27.

Keep Sigachi Industries Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.